GeoVax Prioritizes GEO-MVA and Gedeptin, Discontinues COVID-19 Vaccine Development

GeoVax Labs, Inc. (Nasdaq: GOVX) announced Tuesday a strategic portfolio prioritization that will concentrate its resources on two lead programs—GEO-MVA and Gedeptin—while discontinuing active development of its GEO-CM04S1 COVID-19 vaccine candidate. The decision, which the company said was not based on any safety concerns, reflects the evolving global COVID-19 vaccine market and GeoVax’s shift toward programs with clearer regulatory pathways and more immediate commercialization potential.

GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, is advancing under an expedited regulatory pathway supported by European Medicines Agency (EMA) scientific advice. This approach could allow approval based on a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine, potentially accelerating development timelines. The company has already manufactured and released clinical-grade material for a planned Phase 3 immunobridging study, expected to begin in the second half of 2026. Upon successful completion, GEO-MVA could move toward regulatory submission and potential commercialization, including emergency use licensing.

GeoVax has initiated outreach to global procurement and preparedness stakeholders, including government agencies, international organizations, and biodefense programs, to explore potential vaccine supply agreements for national stockpiling and outbreak response. The company positions GEO-MVA as a critical additional supplier of MVA vaccines to support supply-chain resilience and biodefense preparedness. This move comes amid ongoing global efforts to secure mpox vaccines following outbreaks in 2022 and continued sporadic cases worldwide.

In oncology, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) platform, in alignment with emerging immuno-oncology treatment paradigms. The company highlighted the landmark KEYNOTE-689 Phase 3 trial, which demonstrated improved event-free survival with neoadjuvant checkpoint inhibitor therapy in resectable head and neck cancers. GeoVax’s planned Phase 2 study (AdPNP-203) will evaluate Gedeptin in combination with pembrolizumab and fludarabine in a neoadjuvant setting, aiming to enhance tumor immune visibility and improve clinical outcomes. Gedeptin’s mechanism involves localized generation of a potent chemotherapeutic agent that damages treated lesions and sensitizes tumors to checkpoint inhibitors, potentially expanding response rates in patients who derive limited benefit from checkpoint inhibition alone.

David Dodd, Chairman and CEO of GeoVax, stated, “GeoVax is at an important inflection point, and this decision reflects a deliberate and disciplined focus on the programs we believe can deliver the greatest near-term and long-term value.” He emphasized that portfolio prioritization is standard in the biotechnology industry, enabling companies to align resources with the highest-value opportunities as market conditions evolve.

The discontinuation of GEO-CM04S1 highlights the shrinking COVID-19 vaccine market, which has seen reduced demand and a shift toward annual boosters. By reallocating resources, GeoVax aims to accelerate its mpox/smallpox vaccine program, which addresses ongoing biodefense and public health needs, and its oncology pipeline, which targets a growing area of cancer treatment. The company’s strategic pivot underscores its commitment to programs with stronger demand visibility and clearer regulatory paths, positioning it for potential late-stage development and commercialization.

For more information, visit www.geovax.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is GeoVax Prioritizes GEO-MVA and Gedeptin, Discontinues COVID-19 Vaccine Development.

The post GeoVax Prioritizes GEO-MVA and Gedeptin, Discontinues COVID-19 Vaccine Development appeared first on citybuzz.